Mydekla

Daclatasvir is a direct-acting antiviral (DAA) agent. It targets the NS5A and then causes a fall in serum HCV RNA levels. It works to disrupt HCV replication by specifically inhibiting the critical functions of an NS5A protein in the replication complex. It is demonstrated that it causes downregulation of the hyperphosphorylation of NS5A. When given at three times the maximum recommended dose, it does not prolong the QT interval. NS5A is a viral nonstructural phosphoprotein. It is part of a functional replication complex in charge of viral RNA genome amplification on endoplasmic reticulum membranes. It binds to HCV RNA. To maintain the HCV replication complex is mediated by the cis-acting function of basally phosphorylated NS5A and the trans- the trans-acting function of hyperphosphorylated NS5A works to modulate HCV assembly and infectious particle formation. Daclatasvir disrupts hyperphosphorylated NS5A proteins and interferes with the function of new HCV replication complexes. Daclatasvir also blocks both intracellular viral RNA synthesis and virion assembly/secretion in vivo.

Mydekla 60mg tablet may cause certain side effects. If side effects occur after administration or last longer than usual, contact your healthcare professional.

Fatigue

Headache

Nausea

Insomnia (difficulty in sleeping)

Anemia

Diarrhea

Skin rash

Dizziness

Drowsiness

Unusual tiredness

Vomiting

Take Mydekla 60 mg tablet exactly as your healthcare provider tells you. Do not skip the dose. Do not crush or chew the tablet. Administer this tablet only if your healthcare provider prescribes it.

Seek immediate medical attention in case of overdose.

If you miss a dose, make sure to take it as soon as you remember. Skip the missed dose in case it is already the time for your next scheduled dose. Do not double the dose to catch up.